Therasis

Therasis Inc. is a new drug discovery company developing oncology therapeutics for use as single agents or in combination therapy. The Company’s proprietary technology, the Therasis Filter™, represents a paradigm shift in the ability to discover therapeutic targets, their chemical inhibitors, and associated biomarkers. This platform integrates world-class expertise in high throughput screening, systems biology, cancer genetics and clinical research. Therasis plans to leverage its discovery engine to identify new chemical entities for internal development and to forge collaborations with pharmaceutical and biotechnology companies on drug repositioning.

Therasis’ technology platform was developed at Columbia University by internationally recognized thought leaders in cancer genetics, cancer systems biology, and cancer therapeutics development. The Company is funded by Tilocor Life Science which is the investor arm of Tilocor group.

Therasis headquartered in New York, New York, United States, North America, operates in the Biotechnology, Therapeutics, Genetics, Health Diagnostics, Oncology sector. The company focuses on Biotechnology and has secured $240.0M in funding across 20 round(s). With a team of 1-10 employees, Therasis is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Therasis, raised $12.0M. Discover more about their projects, partnerships, and impact on our platform.